Navigation Links
A Greater Effect on Depressive Symptoms than Current Treatments is One of the Greatest Unmet Needs in Treatment-Resistant Depression
Date:5/1/2013

BURLINGTON, Mass., May 1, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a greater effect on depressive symptoms than current treatments is one of the greatest unmet needs in patients with treatment-resistant depression (TRD)*, according to insights from surveyed psychiatrists in the United States and Europe as well as U.S. managed care organizations' (MCOs') pharmacy directors. Pharmacological treatment for TRD most typically involves switching, combining (two antidepressants from different classes) or augmenting (combining another agent with an antidepressant). The atypical antipsychotics Abilify (Bristol-Myers Squibb/Otsuka Pharmaceutical's aripiprazole) and Seroquel XR (AstraZeneca's quetiapine XR, generics in the United Kingdom and Germany) are two therapies approved as adjunct therapies to antidepressants in the U.S. and are also used in this patient population.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO

"Adjunctive treatment with atypical antipsychotics, though considered effective by thought-leaders, generally results in significant weight gain, and so emerging therapies could differentiate themselves in the marketplace by demonstrating both efficacy in TRD and by having a more tolerable weight gain profile," said Decision Resources Analyst Alana Simorellis , Ph.D.

The DecisionBase 2013 report entitled In the Crowded Antidepressant Market Space, What Are the Remaining Opportunities for New Therapies for TRD? also finds that surveyed pharmacy directors are more receptive to a therapy offering improvements in depressive symptoms over aripiprazole compared with a therapy offering improvements in weight gain or sexual dysfunction. This finding suggests that cost-sensitive payers consider efficacy improvements to be of greater value than improvements in tolerability.

Surveyed U.S. psychiatrists expect to prescribe Eli Lilly's emerging therapy edivoxetine to 25 percent of their patients with TRD. Decision Resources forecasts that edivoxetine will earn a U.S. patient share for TRD similar to surveyed psychiatrists' estimate by 2021, based on top-line results from Phase II/III trials of edivoxetine as an adjunct therapy to SSRIs and positive Phase II/III monotherapy results in patients with major depressive disorder.

Clinical data and the opinions of interviewed thought leaders indicate that, among emerging therapies profiled in the report, Eli Lilly's edivoxetine shows considerable promise as an adjunct to antidepressant therapy. Additionally, edivoxetine appears to offer a more favorable profile in terms of neurological side effects and risk of weight-gain relative to the atypical antipsychotics.

*The majority of physicians interviewed and surveyed by Decision Resources consider a patient "treatment-resistant" if depressive symptoms persist despite treatment with at least two different trials of antidepressant drugs from two different drug classes.

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

 

 

 


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Smart911 and In Case of Emergency Standard Partner to Enhance Availability of Life Saving Data for Greater Emergency Response
2. Cancer drug shortages mean higher costs and greater risk for patients
3. New Report Details NCPA Efforts to Drive Greater Medication Adherence
4. Greater New York Dental Meeting and Inside Dental Technology Announce Collaboration 2013
5. Survey: Hospital Executives Nationwide Facing Operating Room Case Volume Increases, Seeking Greater Efficiency through Healthcare Information Technology (HIT)
6. Diabetes Care Devices in Emerging Countries (China, India, Brazil) to 2017 - Greater Awareness is Increasing Demand for Self-Monitoring of Blood Glucose (SMBG) in the Home Care Segment
7. Xiangxue Pharmaceuticals to Acquire Rights for a Promising Drug Candidate from Kinex Pharmaceuticals for the Greater China Territory
8. Smith & Nephew launches revolutionary open-architecture suture anchor for rotator cuff repair with greater pullout strength than competitors[i]
9. Organogenesis to Present Large Retrospective Comparative Effectiveness Analysis and Health Economic Data in Chronic Wound Healing at The Symposium on Advanced Wound Care and Wound Healing Society Meeting
10. For Treating Clostridium difficile Infections, Surveyed Infectious Disease Specialists Agree That Effect on Recurrence Rate is One of the Drug Attributes that Most Influences Their Prescribing Decisions
11. Deploying an Effective Pay for Performance Bonus System that Works Across Multiple Industry Sectors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Global MEMS Devices Medical Market Analysis 2016 - Forecast to ... The report contains up to date financial ... reliable analysis. Assessment of major trends with potential impact on ... dive analysis of market segmentation which comprises of sub markets, ...
(Date:6/23/2016)... 2016 Bracket , a leading clinical trial ... clinical outcomes platform, Bracket eCOA (SM) 6.0, at the ... – 30, 2016 in Philadelphia , Pennsylvania.  ... Assessment product of its kind to fully integrate with RTSM, ... eCOA 6.0 is a flexible platform for electronic clinical outcomes ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s ... setting the bar too high can result in disappointment, perhaps even self-loathing. However, those ... goal. , Research from PsychTests.com reveals that behind the tendency to ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out ... family verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers ... would throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
(Date:6/24/2016)... New York, NY (PRWEB) , ... June 24, ... ... lifestyle publication Haute Living, is proud to recognize Dr. Barry M. Weintraub as ... believes that “the most beautiful women in the world, and the most handsome ...
(Date:6/24/2016)... ... ... Venture Construction Group (VCG) sponsors Luke’s Wings 5th Annual ... Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The event raised funds ... been wounded in battle and their families. Venture Construction Group is a 2016 Silver ...
Breaking Medicine News(10 mins):